A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve

NCT01110707 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Infertility
Ovulation Induction

Interventions

DRUG: Recombinant human follicle stimulating hormone (r-hFSH)
DRUG: Recombinant human luteinizing hormone (r-hLH)

Sponsor

Merck KGaA, Darmstadt, Germany